ArticleBiomedical optics express2026
Intrinsically co-registered extended-depth-of-focus OCM and two-photon microscopy for label-free volumetric analysis of 3D cell models.
Article in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intrinsically co-registered extended-depth-of-focus OCM and two-photon microscopy for label-free volumetric analysis of 3D cell models.Biomedical optics express · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beam engineering effectively overcomes the resolution-depth of focus trade-off in high-NA optical coherence microscopy (OCM). Conventional OCM is limited by this constraint, hindering stable volumetric acquisition. To overcome this, we present an intrinsically registered imaging platform based on Bessel beam-enabled extended-depth-of-focus OCM for quantitative, label-free volumetric phenotyping of three-dimensional cell models. Annular illumination extends the focal range to 193 µm, enabling stable scattering contrast in dense spheroids. By exploiting structural scattering signatures associated with cellular disintegration, we demonstrate volumetric viability mapping with 94.57 ± 2.69% aggregate viability concordance relative to fluorescence references. The platform differentiates drug-specific responses and captures pathological transitions in spheroids and organoids, establishing a quantitative paradigm for volumetric biological phenotyping.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.